Detalles de la búsqueda
1.
Optimization of therapeutic T cell expansion in G-Rex device and applicability to large-scale production for clinical use.
Cytotherapy;
24(3): 334-343, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35063359
2.
BL-01, an Fc-bearing, tetravalent CD20 × CD5 bispecific antibody, redirects multiple immune cells to kill tumors in vitro and in vivo.
Cytotherapy;
24(2): 161-171, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34538717
3.
Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.
Invest New Drugs;
36(1): 85-95, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28726132
4.
Cord blood-derived cytokine-induced killer cells combined with blinatumomab as a therapeutic strategy for CD19+ tumors.
Cytotherapy;
20(8): 1077-1088, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30093325
5.
A novel method using blinatumomab for efficient, clinical-grade expansion of polyclonal T cells for adoptive immunotherapy.
J Immunol;
193(9): 4739-47, 2014 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25267972
6.
Vascular endothelial growth factor c promotes ovarian carcinoma progression through paracrine and autocrine mechanisms.
Am J Pathol;
184(4): 1050-1061, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24508126
7.
A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity.
Nat Chem Biol;
4(6): 357-65, 2008 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-18469809
8.
Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing.
Bioorg Med Chem;
18(5): 1844-53, 2010 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20153204
9.
Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer.
J Natl Cancer Inst;
108(1)2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26563355
10.
3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 2. Lead optimization.
J Med Chem;
48(8): 2944-56, 2005 Apr 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-15828833
11.
The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.
Mol Oncol;
8(8): 1495-507, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24962792
12.
The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia.
PLoS One;
8(3): e58424, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23520509
13.
NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies.
Mol Cancer Ther;
11(4): 1006-16, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22319201
14.
Therapeutic efficacy of the pan-cdk inhibitor PHA-793887 in vitro and in vivo in engraftment and high-burden leukemia models.
Exp Hematol;
38(4): 259-269.e2, 2010 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-20167248
15.
Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-Ras(G12D)LA2 lung adenocarcinoma transgenic mouse model: evaluation by multimodality imaging.
Mol Cancer Ther;
9(3): 673-81, 2010 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-20197397
16.
Phosphorylation of TCTP as a marker for polo-like kinase-1 activity in vivo.
Anticancer Res;
30(12): 4973-85, 2010 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21187478
17.
Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy.
Mol Cancer Ther;
9(8): 2243-54, 2010 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-20682657
Resultados
1 -
17
de 17
1
Próxima >
>>